BALTIMORE, Jan. 28 /PRNewswire/ -- Lentigen Corporation today announced the appointment of Tim Ravenscroft as chief executive officer.
David Wetherell, Lentigen's chairman, commented, "The board of Lentigen is delighted that Tim has agreed to lead Lentigen, as we are about to enter clinical trials for our first therapies later this year for Glioblastoma and GVHD. His particularly strong background and global leadership in healthcare products will serve Lentigen well as we advance with our broad set of product lines, therapeutics and collaborations."
Having most recently served as president of Bristol-Myers Squibb (BMS) Medical Imaging, Mr. Ravenscroft has more than 29 years' international experience in healthcare product development and commercial management. He has also held executive and senior positions with BMS' Global Virology Franchise, Dupont Pharmaceutical's Global HIV Business, and Glaxo Wellcome.
"Tim's strong background in HIV at BMS, DuPont and Glaxo Wellcome further bolsters Lentigen as we consider our own initiatives and collaborations in this arena," said Mr. Wetherell. "Certainly, the world needs superior solutions to address this disease, and with Tim's presence, Lentigen is better positioned than ever to play a key role."
Mr. Ravenscroft said, "Lentigen is poised to take a leading role in areas of biomedicine where Lentiviral vectors can play a decisive role. The company has a clear commitment to the improvement of health outcomes for patients in several disease areas and I am greatly looking forward to leading the corporation through its further growth and development."
Lentigen's founder Dr. Boro Dropulic, who will retain the roles of president and chief scientific officer, commented, "I am delighted that Tim has joined Lentigen and I look forward to an effective partnership that will take Lentigen to the next level."
Mr. Ravenscroft holds a bachelor's degree in applied biology from North
|SOURCE Lentigen Corporation|
Copyright©2008 PR Newswire.
All rights reserved